KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA

GENETIC2 trials

Sponsors

Institut de Cancérologie de Lorraine

Conditions

Colorectal Cancer MetastaticMetastatic Colorectal Cancer

Unknown Phase

Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer

CompletedNCT02751177

Institut de Cancérologie de LorraineColorectal Cancer Metastatic

Start: 2016-03-25End: 2017-05-30Updated: 2018-08-09

Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

CompletedNCT02827565

Institut de Cancérologie de LorraineMetastatic Colorectal Cancer

Start: 2016-02-03End: 2017-01-19Updated: 2018-08-08

Related Papers

Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study.

2025-10-30

cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

Journal of Clinical Oncology2019-05-2010 citations